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Abstract
Background: Enhanced external counter pulsation (EECP) is a non-invasive treatment option for
patients with refractory angina pectoris ineligible to further traditional treatment. The aim of this
study was to evaluate the effect of EECP on patients at a Scandinavian medical centre and to
investigate if outcome can be predicted by analysing baseline factors.
Methods: 86 consecutive patients (70 male, 16 female) were treated with EECP and followed for
two years post treatment. Canadian cardiovascular society (CCS) class was analysed, and
medication and adverse clinical events were researched prior to EECP, at the end of the treatment,
and at six, 12 and 24 months thereafter. Patients responding to therapy by improving at least one
CCS class were compared with those who failed to respond. Any differences in background factors
were recorded and analysed.
Results: 79% of the patients responded to therapy by improving at least one CCS class. In general,
the CCS class improved by one class after EECP treatment (3.05 before versus 2.14 after
treatment). A total of 61.5% of the initial responders showed sustained improvement at the 12
month follow-up while 29% presented sustained improvement after 24 months. Treatment was
most effective among patients suffering from CCS class III-IV angina pectoris, while patients
suffering from CCS class II angina pectoris improved transiently but failed to show sustained
improvement after the 12 month follow-up. Diabetes mellitus and calcium channel antagonists
were more common among the non-responders (p < 0.05).
Conclusion: This study confirms the safety and efficiency of EECP as a treatment option for
patients suffering from refractory angina pectoris. The therapy is most beneficial in patients
suffering from severe angina (CCS III-IV) while sustained response to therapy could not be verified
among patients suffering from CCS class II angina pectoris.
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Background
Stable angina pectoris is a common and sometimes disa-
bling disorder characterized by chest pain due to ischemia
of the myocardium, generally caused by obstruction or
spasm of the coronary arteries. Atherosclerosis of coro-
nary vessels is the main cause of angina pectoris while cor-
onary artery spasm is seen in a minor number of angina
pectoris patients. Other causes such as connective tissue
disorders, valvular disease and arrhythmia are even less
common.
Prevalence of angina pectoris increases with age in both
males and females. It has been estimated that 2–4% of the
adult European population is affected by angina pectoris
[1]. This number is likely to increase further since life
expectancy continues to improve worldwide.
Treatment of angina pectoris is traditionally aimed at
reduction of symptoms as well as prevention of future car-
diac events such as myocardial infarction or death. Phar-
macological agents such as nitrates, aspirin, beta-
adrenoreceptor antagonists and calcium channel blockers
are used [2] as well as surgical therapies aimed at restoring
blood flow, e.g. coronary artery bypass graft (CABG) or
percutaneous coronary intervention (PCI) [3]. As many as
15% of the patients either fail to respond fully to therapy
as described above or are ineligible to further interven-
tion, thus said to suffer from refractory angina pectoris
[4]. These patients suffer from marked limitation of every-
day physical activity due to their pain, which in some
cases are more or less constant. In the last few years, the
lack of efficient therapy for refractory angina pectoris in
combination with increased survival rates after myocar-
dial infarction and an ageing population has caused
increased need for new therapeutic methods. Intense
research has yielded methods such as laser revasculariza-
tion, left stellate ganglion blockade, spinal cord stimula-
tion (SCS) and enhanced external counterpulsation
(EECP)[3].
EECP is a non-invasive method used to treat patients with
refractory angina pectoris, ineligible to further pharmaco-
logical or surgical intervention. Pneumatic cuffs are
applied to the lower limbs and set to inflate sequentially
during diastole and deflate before the onset of systole.
This causes an increased diastolic pressure resulting in
augmented coronary blood flow [5] as well as increased
venous return [6] and improved cardiac output [7]. The
systolic blood pressure is lowered due to deflation before
systole, thereby decreasing afterload and preventing heart
failure and pulmonary oedema [8].
The aim of the current study was to assess the two-year
outcome of EECP treatment of refractory angina pectoris
and to determine whether the response to treatment can
be predicted by analysis of baseline factors.
Methods
Patients
A total of 86 consecutive patients (70 male, 16 female)
were treated with EECP and followed for two years after
completion of treatment.
Referral, treatment and follow-ups were conducted at the
Central hospital in Kristianstad in southern Sweden. All
patients had angiographically verified significant stenosis
in at least one major coronary artery. Patients were consid-
ered at optimal pharmacological treatment and unsuita-
ble for further revascularization by the time of referral as
evaluated by a board of cardiologists and thoracic sur-
geons at the Lund University hospital. Anginal status,
medical history, glyceryl trinitrate (GTN) consumption
and demographics were obtained at baseline with follow-
up immediately after treatment, at 6, 12 and 24 months
after therapy. Pharmacological treatment was adjusted
whenever the need for adjustments arose.
Patients were divided into two groups depending on
response to therapy. Those who improved at least one
Canadian cardiovascular society (CCS) class after treat-
ment were considered responders whereas those who
failed to respond to therapy were considered non-
responders at the immediate follow-up. Baseline factors
(Table 1) were compared between the two groups in an
attempt to find factors predisposing patients to treatment
failure. Patients had a long history of coronary artery dis-
ease (mean duration 11.5 years) and risk factors for arte-
riosclerosis were common. Most patients had suffered
from one or more acute myocardial infarctions, most of
which had been treated with either PCI or CABG.
Informed written consent was obtained from all patients
included in the study. The study was conducted in accord-
ance with the declaration of Helsinki and ethical guide-
lines determined by the ethics council at Lund University.
Patients who were forced to leave the follow-up due to the
need of a new course of treatment were considered to have
fallen back to the same CCS class as at referral.
EECP
The EECP device consists of three paired pneumatic cuffs
applied to the calves, thighs and buttocks (Vasomedical,
Westbury, New York, USA). The cuffs are inflated sequen-
tially, applying 250 – 300 mmHg of external pressure dur-
ing diastole, causing the return of blood from the legs to
the central circulation and producing aortic diastolic aug-
mentation thus increasing both venous return and cardiac
output. The cuffs are then rapidly deflated at the end of
the diastole (thereby) reducing peripheral resistance andBMC Cardiovascular Disorders 2008, 8:39 http://www.biomedcentral.com/1471-2261/8/39
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cardiac afterload. Treatment was given as 35 one-hour ses-
sions administered five days a week for seven consecutive
weeks.
Statistics and calculations
All calculations and statistics were performed using
GraphpadPrism 4.0. Descriptive data are presented as
mean and standard error of the mean (SEM) or median
and range depending on whether the material is normally
distributed or not. Statistical significance was assumed
when p < 0.05. Student's t-test was used when comparing
two groups and Fisher's exact test or the chi-2-test was
used when comparing baseline factors between respond-
ers and non-responders. AVOVA with Dunn's post hoc
test was used when comparing more than two groups. The
risk for mass significance was not taken into consideration
when analysing the results.
Results
Response to therapy
Response to therapy, defined as improvement by at least
one CCS class, was seen in 79% of the patients. Among
the responders, 13% improved two CCS classes or more.
Failure to respond to therapy occurred in 21% of the
patients. Two patients among the non-responders had
improved their CCS class at the 6 months follow-up in
spite of failure to respond immediately after therapy.
During follow-up, sustained response to therapy was seen
for at least 12 months among 61.5% of the responding
patients, while 29% of the patients maintained a response
to therapy for at least 24 months (p < 0.001 and < 0.01 vs.
pre-treatment, figure 1). Patients in CCS class III and IV at
referral maintained response to therapy for at least 24
months in 22.4% and 70% of the cases, respectively.
Patients in CCS class II at referral showed initial response
to therapy, but failed to maintain the reduction in anginal
status for 24 months (figure 2).
Table 1: Baseline characteristics
Total, n = 78 Responders, n = 62 Non-responders, n = 16 p
Gender 63M/15F 49M/13F 14M/2F 0.72
Age at referral 66, 43–87 64, 43–87 71, 55–84 0.14
Beta-adrenoceptor antagonists 57 45 12 1.00
Ca2+-channel antagonists 35 24 11 < 0.05
Long-lasting nitrates 58 45 15 0.10
Warfarin 6 4 2 0.60
Aspirin 67 53 14 1.00
ACEI or ARB 36 26 10 0.17
Diuretics 27 19 8 0.24
Lipid lowering agents 64 50 14 0.72
Insulin 11 7 4 0.22
Oral antidiabetics 8 3 5 < 0.01
Diabetes 16 9 7 < 0.02
Hypertension 26 19 7 0.38
Atrial fibrillation 3 2 1 0.50
Current smoker 3 3 0 1.00
Myocardial infarction 47 38 9 0.78
CABG 57 44 13 0.54
PCI 45 37 8 0.57
CABG or PCI 66 51 15 0.44
Pacemaker 6 3 3 0.10
CCS IV 12 10 2 0.46
CCS III 58 47 11
CCS II 8 5 3
CCS I 0 0 0
Years with CAD 11.5, 1–35 11.5, 1–35 11, 2–33 0.98
EF > 50% 48 39 9 0.76
EF 50 – 41% 14 10 4
EF 40 – 30% 14 11 3
EF < 30% 2 2 0
EECP = enhanced external counterpulsation, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin type I receptor blocker, CABG = 
coronary artery bypass graft, PCI = percutaneous coronary intervention, CCS = Canadian Cardiovascular Society classification, CAD = coronary 
artery disease, EF = ejection fraction.BMC Cardiovascular Disorders 2008, 8:39 http://www.biomedcentral.com/1471-2261/8/39
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The CCS class improved by, in general, one class after
EECP treatment (3.05 before versus 2.14 after treatment).
Weekly GTN usage was reduced in 64% of the patients (p
< 0.001, Table 2) and none of the patients had to increase
their use of short acting nitrates after completing EECP
therapy.
Anginal status did not worsen in any of the patients after
EECP treatment.
Adverse events
Eight patients suffered from adverse events during the
EECP therapy and had to terminate their treatment pre-
maturely, including 2 patients who died due to myocar-
dial infarction (Table 3). These patients were excluded
from the follow-up investigations. A total of 13 patients
had to abort their participation in the follow-up (Table 4).
Ten of them left due to recurring angina pectoris in need
of further EECP treatment. These patients are included in
the study, but calculations were adjusted as if they
relapsed to pre-EECP CCS class at the time of abortion.
One patient left the follow-up program satisfied with his
current anginal status and did not wish to participate in
further evaluation. Three patients died during the follow-
up. The cause of death remains unknown in the first case
Overall changes in CCS class before EECP, after EECP and  during follow-up Figure 1
Overall changes in CCS class before EECP, after 
EECP and during follow-up. The figure shows marked 
reduction in the number of patients suffering from severe 
angina pectoris after treatment and during the follow-up 
period.
Changes in CCS class over time Figure 2
Changes in CCS class over time. The figure shows CCS 
class distribution over time, subdivided into groups depend-
ing on CCS class at referral. A = CCS II, B = CCS III and C = 
CCS IV at referral.BMC Cardiovascular Disorders 2008, 8:39 http://www.biomedcentral.com/1471-2261/8/39
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while the second patient died from cardiac faliure and the
third patient from end-stage amyloidosis.
Analysis of background factors
Diabetes mellitus, use of calcium channel blockers and
use of oral antidiabetic agents were each more common
among non-responders than among those responding to
therapy (p < 0.05, p < 0.05 and p < 0.01, respectively, Table
1). The other baseline factors studied did not affect the
outcome of EECP treatment (Table 1).
Smoking and previous myocardial infarction were more
common among patients that were forced to withdraw
from the follow-up due to recurring angina pectoris (both
p < 0.05).
Discussion
The present study is a follow-up study performed on the
results of EECP treatment of patients with refractory
angina pectoris at a major Scandinavian medical centre
for EECP. A majority of the patients were men suffering
from long time extensive coronary artery disease refrac-
tory to further medical or surgical therapy. This study con-
firms the safety and efficiency of EECP as a method for
reducing CCS class scores in patients with refractory
angina pectoris. The reduction in anginal symptoms
lasted for up to two years. These results are in accordance
with similar studies of long term benefit performed at
American medical centres [9-11]. Five patients died dur-
ing the study, three patients during the follow-up and two
during the actual treatment. This is well within what can
be expected in this group of patients with end stage coro-
nary artery disease. The overall mortality among a similar
set of patients receiving SCS has been shown to be 7–8%,
the majority due to cardiac death [12]. Studies where
other modes of treatment for refractory angina pectoris
have been used report an annual in-treatment mortality of
5–17% [13]
The exact mechanism by which EECP exerts its effect on
the cardiovascular system is not fully known. The imme-
diate benefits are similar to those provided by the intra-
aortic balloon pump, namely increased blood flow
through coronary vessels during diastole and decreased
afterload during systole [5]. EECP has been shown to be
more efficient than intra-aortic balloon pumping in
increasing venous return and enhancing cardiac output
[6].
Long term effects of EECP treatment are thought to be
mediated through shear stress on the vascular endothe-
lium, which in turn triggers angiogenesis and improves
vascular endothelial function [14] due to modulated
release of vasoactive substances such as endothelin [15],
nitric oxide [15] and vascular endothelial growth factor
[16]. Improvement in oxygen uptake after treatment with
EECP implies alterations in cellular metabolism as well as
hemodynamic improvement [16,17]. EECP has been
shown to extend time until exercise-induced ischemia
occurs [18]. This may be caused by lowered oxygen
demand due to lowered left ventricular afterload and opti-
mization of aortic augmenting index [19]. Relief in myo-
cardial ischemia as well as improved quality of life has
been shown in a number of studies [20,21]
Improvement in quality of life may at least in part be due
to a placebo effect as described by Springer et al [15], but
since the current patients suffer from end stage coronary
artery disease, are incapacitated and without conventional
treatment options, any additional treatment that relieves
their pain without adverse effect on their condition is
worth taking into consideration. Available, data suggest
Table 2: GTN usage before and after treatment
Before EECP After EECP
0 administrations/week 9 30
1–2 administrations/week 7 16
3–7 administrations/week 17 19
> 7 administrations/week 44 7
Data missing 1 6
EECP = Enhanced external counterpulsation.
Table 3: Adverse events during treatment
Patients (gender, age) EECP sessions before termination Cause of termination
Male, 50 12 Increased chest pain
Male, 84 15 Death due to myocardial infarction
Female, 57 2 Emesis
Male, 58 6 Hiatus hernia
Male, 53 25 Biliary colics
Male, 77 9 Hemorrhoids
Male, 74 25 Chest pain
Male, 59 9 Death due to myocardial infarction
EECP = Enhanced external counterpulsation.BMC Cardiovascular Disorders 2008, 8:39 http://www.biomedcentral.com/1471-2261/8/39
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that EECP improves coronary and systemic perfusion by
enhancing function of the vascular endothelium, by
favouring angiogenesis and reducing oxygen consump-
tion.
The results from the present study indicate that the out-
come of EECP treatment depends on CCS class at referral
("the worse the better"), and negatively on the presence of
diabetes mellitus and calcium channel blockers. CCS class
II at referral and diabetes [22,23], have previously been
described as predisposing to treatment failure. Further
studies have to be conducted in order to determine the
exact mechanism by which they impair the therapeutic
effect of EECP. A possible explanation can however be
hypothesized when it comes to calcium channel blockers.
Calcium channel blockers act as vasodilators reducing
total peripheral resistance. A patient under the influence
of calcium channel blockers might fail to mount further
vasodilatation, thereby reducing or obliterating the
peripheral effect of EECP treatment since dilated blood
vessels suffer from less shear stress than occluded ones.
Thus, the treatment may be more effective in patients with
severe vascular narrowing.
The duration of sustained improvement might be
impaired by smoking as seen among those patients who
had to cancel their follow-up due to recurring angina pec-
toris. The explanation could be local effect on the vascular
endothelium since tobacco smoking is known to cause
endothelial dysfunction [24,25], thereby negating the
beneficial effects of shear stress and release of vasoactive
factors in the long run.
The present study confirms previous results that EECP is a
safe and efficient method to alleviate the symptoms in
severe refractory angina. The effects on long time mortal-
ity are however yet to be determined. Further studies on
background factors associated with reduced response to
EECP are needed to confirm the findings presented in this
study.
Limitation of the study
This follow-up report does not include a control group,
making the placebo effect a possible confounding factor.
The obvious effect of EECP could therefore, at least in
part, be the result of increased attention to the patients
during treatment and follow-up. Evidence from this and
previous studies suggest that EECP treatment is effective in
limiting symptoms of severe angina pectoris. No such
conclusions can be made of the effect on mortality. Small
differences in background factors can be difficult to detect
in a material of this size. The possibility of mass signifi-
cance in the analysis of background factors associated
with treatment failure cannot be ruled out since multiple
statistical analyses has been performed on the same mate-
rial. This has to be taken into consideration while evaluat-
ing the results of this study. In the results section, some
data (average CCS class) is presented as mean when it is
ordinal rather than continuous. This is a common
approach in biomedical literature, but should be pointed
out.
Conclusion
This study confirms the safety and efficiency of EECP as a
treatment option for patients suffering from severe angina
pectoris refractory to further pharmacological or surgical
intervention. Therapy is most beneficial for those in CCS
class III and IV who demonstrated a sustained improve-
ment at the two year follow-up. No such long term
response to therapy could be verified among patients with
CCS class II angina pectoris at referral. Diabetes mellitus
and calcium channel blockers were each significantly
Table 4: Adverse events during follow-up
Patients (gender, age) Months in follow-up before termination Cause of termination
Male, 52 9 Relapsing angina*, CCS III
Male, 70 11 Withdrawal from follow-up
Male, 64 9 Relapsing angina*, CCS III
Male, 71 10 Relapsing angina*, CCS III
Male, 66 9 Relapsing angina*, CCS IV
Male, 62 8 Relapsing angina*, CCS III
Male, 73 14 Relapsing angina*, CCS III
Male, 53 12 Relapsing angina*, CCS III
Male, 57 10 Relapsing angina*, CCS III
Male, 74 20 Death due to pneumonia and cardiac failure
Male, 71 10 Relapsing angina*, CCS III
Male, 71 4 Death of unknown causes
Female, 79 14 Death due to amyloidosis
Male, 71 21 Relapsing angina*, CCS III
* = Patients with relapsing angina pectoris in need of further therapy during the follow-up. CCS = Canadian Cardiovascular Society classification.BMC Cardiovascular Disorders 2008, 8:39 http://www.biomedcentral.com/1471-2261/8/39
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more common among patients who failed to respond to
EECP. Tobacco use and previous myocardial infarction
were associated with early relapse in angina in spite of an
initial response.
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